{"disease":{"id":"ras-mutation","name":"ras mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04185883","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":610,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06500676","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":407,"lead_sponsor_name":"Genfleet Therapeutics (Shanghai) Inc.","has_results":false},{"nct_id":"NCT07124884","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT03719690","title":"Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"Kura Oncology, Inc.","has_results":true},{"nct_id":"NCT04776655","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT05136014","title":"Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT07023731","title":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":159,"lead_sponsor_name":"Arvinas Inc.","has_results":false},{"nct_id":"NCT04678648","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"RasCal Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04852250","title":"Centralized Tumour Board and Secondary Intervention Rate in mCRC","phase":"","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Ludwig-Maximilians - University of Munich","has_results":false},{"nct_id":"NCT06720987","title":"A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Kumquat Biosciences Inc.","has_results":false},{"nct_id":"NCT06435455","title":"GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Suzhou Genhouse Bio Co., Ltd.","has_results":false},{"nct_id":"NCT06659341","title":"A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06936527","title":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":102,"lead_sponsor_name":"NovaOnco Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05445843","title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03065387","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":93,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07252479","title":"Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Adlai Nortye Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04620330","title":"A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Verastem, Inc.","has_results":false},{"nct_id":"NCT03597581","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT05375994","title":"Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Verastem, Inc.","has_results":false},{"nct_id":"NCT06270082","title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT04111458","title":"A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05735717","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04560270","title":"CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT03829410","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Cardiff Oncology","has_results":true},{"nct_id":"NCT07064018","title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT07303465","title":"To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ranok Therapeutics (Hangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06456138","title":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT06321081","title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT02642042","title":"Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03087071","title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03965845","title":"A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT06218810","title":"Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03750175","title":"OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -","phase":"","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Karen-Lise Garm Spindler","has_results":false},{"nct_id":"NCT02259114","title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT06056024","title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07121829","title":"Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":44,"lead_sponsor_name":"Day One Biopharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05669482","title":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Verastem, Inc.","has_results":false},{"nct_id":"NCT07468071","title":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07122882","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03244956","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT06970353","title":"Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04965818","title":"Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT05340621","title":"NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"OnKure, Inc.","has_results":false},{"nct_id":"NCT04740190","title":"Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06412198","title":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07492342","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Jianxing He","has_results":false},{"nct_id":"NCT04973163","title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06287463","title":"Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Deciphera Pharmaceuticals, LLC","has_results":false},{"nct_id":"NCT03317119","title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}